Log in

Relevant bibliographies by topics / Cholinesterase Inhibitor / Books

To see the other types of publications on this topic, follow the link: Cholinesterase Inhibitor.

Books on the topic 'Cholinesterase Inhibitor'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 48 books for your research on the topic 'Cholinesterase Inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Ezio, Giacobini, ed. Cholinesterases and cholinesterase inhibitors. Martin Dunitz, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yau, Kenneth Kwok Chi. Assessing and predicting treatment responses to cholinesterase inhibitor pharmacotherapy in Alzheimer's disease. National Library of Canada, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

International Meeting on Cholinesterases (3rd 1990 La Grande Motte, France). Cholinesterases: Structure, function, mechanism, genetics, and cell biology. American Chemical Society, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

1935-, Zakut Haim, ed. Human cholinesterases and anticholinesterases. Academic Press, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Moralev, Serge N. Comparative enzymology of cholinesterases. International University Line, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

(Australia), Materials Research Laboratories, ed. Inhibition of EEL acetylcholinesterase by nerve agents: A stopped-flow study. Dept. of Defence, Materials Research Laboratories, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ezio, Giacobini, and Becker Robert E, eds. Current research in Alzheimer therapy: Cholinesterase inhibitors. Taylor & Francis, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Todd, G. Daniel. Draft toxicological profile for diazinon. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Roney, Nickolette. Draft toxicological profile for guthion. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

National Institute for Clinical Excellence (Great Britain). Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. National Institute for Clinical Excellence, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

E, Chambers Janice, and Levi Patricia E, eds. Organophosphates: Chemistry, fate, and effects. Academic Press, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Bryan, Ballantyne, and Marrs Timothy C, eds. Clinical and experimental toxicology of organophosphates and carbamates. Butterworth Heinemann, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

E, Becker Robert, and Giacobini Ezio, eds. Alzheimer disease: From molecular biology to therapy. Birkhäuser, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

United States. Dept. of the Army., ed. Assay techniques for detection of exposure to sulfur mustard, cholinesterase inhibitors, Sarin, Soman, GF, and cyanide. Headquarters, Dept. of the Army, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

L, Reid John, ed. Hypertension-drug therapy of tomorrow-calcium antagonists/ACE inhibitors combination as first-line treatment?: An international debate. Raven Health Care Communications, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Parker, James N., and Philip M. Parker. Donepezil: A medical dictionary, bibliography, and annotated research guide to Internet references. ICON Health Publications, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

United States. Agency for Toxic Substances and Disease Registry, ed. Toxicological profile for methyl parathion. Agency for Toxic Substances and Disease Registry, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

E, Becker Robert, and Giacobini Ezio, eds. Cholinergic basis for Alzheimer therapy. Birkhäuser, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Takao, Kumazawa, Kruger Lawrence, and Mizumura Kazue, eds. The polymodal receptor: A gateway to pathological pain. Elsevier, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

(Editor), Jean Massoulie, Eric Barnard (Editor), Arnaud Chatonnet (Editor), Francis Bacou (Editor), Bhupendra P. Doctor (Editor), and Daniel M. Quinn (Editor), eds. Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Conference Proceedings Series). An American Chemical Society Publication, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Giacobini, Ezio. Cholinesterases and Cholinesterase Inhibitors: Basic Preclinical and Clinical Aspects. Informa Healthcare, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kitay, Brandon M., and Rajesh R. Tampi. Memantine in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil. Edited by Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari, and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0018.

Full text

Abstract:

This chapter provides a summary of a landmark study on the pharmacological management of cognitive disorders. In patients with moderate to severe Alzheimer disease treated with a cholinesterase inhibitor (donepezil), is the addition of a N-methyl-D-aspartate receptor inhibitor (memantine) a safe and efficacious augmentation strategy? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews ot

APA, Harvard, Vancouver, ISO, and other styles

23

Serge N. Moralev and Eugene V. Rozengart. Comparative enzymology of cholinesterases. International University Line, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Cholinesterase Inhibitors in Alzheimer's Disease. Lippincott Williams & Wilkins, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hopkins, Philip M. Adverse drug reactions in anaesthesia. Edited by Michel M. R. F. Struys. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199642045.003.0022.

Full text

Abstract:

Adverse drug reactions are implicated in more than 40% of anaesthesia-related deaths. Undoubtedly, many more patients experience morbidity from adverse drug reactions. Widely cited definitions of adverse drug reactions encompass common side-effects but this chapter focuses on those that are unexpected reactions to drugs administered by anaesthetists and that occur at normal drug doses. The chapter includes a comprehensive account of malignant hyperthermia, which remains a major contributor to anaesthesia related to deaths. Malignant hyperthermia is a pharmacogenetic condition triggered by pote

APA, Harvard, Vancouver, ISO, and other styles

26

Ramesh C. Gupta, PhD, DABT, FACT, FATS. Toxicology of Organophosphate & Carbamate Compounds. Academic Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Toxicology of Organophosphate & Carbamate Compounds. Academic Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

Giacobini, Ezio. Cholinesterase Inhibitors: Their Role in the Therapeutic Management of Alzheimer's Disease Pocketbook (Medical Pocketbooks). MARTIN DUNITZ, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

Halwe, Sandro. Versuchsprotokoll - Wirkung Von Cholinesterasen und Deren Inhibition Durch Neostigmin. GRIN Verlag GmbH, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Cholinesterase inhibitors for Alzheimer's disease: A systematic review of randomized controlled trials. Canadian Coordinating Office for Health Technology Assessment, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

(Editor), Janice E. Chambers, and Patricia E. Levi (Editor), eds. Organophosphates: Chemistry, Fate, and Effects. Academic Press, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

(Editor), Janice E. Chambers, and Patricia E. Levi (Editor), eds. Organophosphates: Chemistry, Fate, and Effects. Academic Press, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

Ballantyne, Bryan, and Timothy C. Marrs. Clinical and Experimental Toxicology of Organophosphates and Carbamates. Elsevier Science & Technology Books, 2017.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

Behl, Pearl. Differential long-term cognitive, functional, and behavioral effects of cholinesterase inhibitors in Alzheimer's disease. 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

35

Word for Windows Made Simple (Computing Made Simple). Made Simple, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

36

Gill, Sudeep Singh. Patterns of use and adverse events associated with cholinesterase inhibitors in older adults with dementia. 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Becker, Robert E., and Ezio Giacobini. Cholinergic Basis for Alzheimer Therapy. Birkhauser, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

38

Becker, Robert E., and Ezio Giacobini. Cholinergic Basis for Alzheimer Therapy. Birkhauser Verlag, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

39

Becher, Paul G. Insecticidal and cholinesterase-inhibitory bioactivity of indole alkaloids from benthic freshwater cyanobacteria of the genera Fischerella and Nostoc. 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

40

Tousi, Babak. Cognitive Enhancement in Non-Alzheimer’s Dementias. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190214401.003.0004.

Full text

Abstract:

Cognitive enhancement in non-Alzheimer’s dementias has not been studied as extensively as that in Alzheimer’s dementia. This chapter reviews the research on cognitive enhancement for three types of dementia: vascular dementia, dementia with Lewy bodies, and frontal lobe dementia. The chapter reviews both pharmacological and nonpharmacological approaches for treatment of dementia. The focus is on randomized controlled trials for currently available medications, specifically cholinesterase inhibitors and memantine. Major advances in physical and cognitive rehabilitation during the past decade ha

APA, Harvard, Vancouver, ISO, and other styles

41

Bajgar, Jiri. Nerve Agents Poisoning and Its Treatment in Schematic Figures and Tables. Elsevier, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

42

Bajgar, Jiri. Nerve Agents Poisoning and Its Treatment in Schematic Figures and Tables. Elsevier, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

43

Nerve Agents Poisoning and Its Treatment in Schematic Figures and Tables. Elsevier Science & Technology Books, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

44

Carlock, Linda L. Blood and brain cholinesterase inhibition and associated behaviors from exposure to phosphorodithioate organophosphorus pesticides: Implications for monitoring avian wildlife. 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

45

Cholinergic Basis for Alzheimer Therapy. Birkhäuser Boston, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

46

Cummings, Jeffrey L., and Kate Zhong. Clinical Trials and Drug Development in Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0018.

Full text

Abstract:

This chapter describes the common therapeutic targets, approaches to clinical trial design, biomarkers, and therapeutic interventions across neurodegenerative disorders (NDDs). Each unique NDD-Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), etc.-has a unique phenotype associated with the regional cell population most affected. Each disease, however, is associated with protein misfolding, oxidation, inflammation, apoptosis, and cell death. If vulnerable cell populations include transmitter source nuclei, transmitter deficits also emerge (e.g. cholinergic

APA, Harvard, Vancouver, ISO, and other styles

47

Kuwabara, Satoshi. Neuromuscular junction disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199658602.003.0014.

Full text

Abstract:

Ten seminal papers on disorders of the neuromuscular junction are described, covering historical aspects, recent advances in immunological, biological, and genetic researches, and future perspectives. Early descriptions of myasthenia gravis (MG) date back to the seventeenth century, and MG acquired its name in the nineteenth century. The first symptomatic treatment with cholinesterase inhibitors was reported in 1934, leading to the development of modern immunological therapies. Following the discovery of anti-MuSK (muscle-specific tyrosine kinase) antibody in 2001, MG is currently classified i

APA, Harvard, Vancouver, ISO, and other styles

48

(Editor), T. Kumazawa, L. Kruger (Editor), and K. Mizumura (Editor), eds. The Polymodal Receptor - A Gateway to Pathological Pain (Progress in Brain Research). Elsevier Science, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!